Exciting new therapy for Waldenstrms macroglobulinemia: ibrutinib plus rituximab
Data from the exciting iNNOVATE study (NCT02165397) of ibrutinib plus rituximab for patients with Waldenstrms macroglobulinemia (WM) were presented at the 23rd congress of the European Hematology As...
Author: VJHemOnc
Added: 08/15/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer & Oncology | Hematology | Macroglobulinemia | Politics | Rituxan | Study | Waldenstrom's Macroglobulinemia